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TRIAL OF AMIODARONE FOR EBOLA
Concerns about the off-licence use of amiodarone for
Ebola
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1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; 2Ysbyty Gwynedd, Bangor, UK;
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Wewere disturbed by your article promoting the compassionate
use of amiodarone for Ebola virus disease by the
non-governmental organisation (NGO), Emergency, which
suggested its use was endorsed by the Department for
International Development and WHO.1
Healthcare professionals working within the wider medical
community in Sierra Leone have expressed serious concern
about the off-licence use of this potentially toxic drug in
suspected and confirmed Ebola without the patient’s consent.
Amiodarone has well documented cardiac, hepatic, and
pulmonary side effects.2 3 Evidence of benefit in Ebola virus
disease is speculative at best, and amiodarone is not considered
a priority novel drug for Ebola by WHO, further questioning
the ethics of its use in the current outbreak.4 This use of
amiodarone, and other unconventional practices—such as the
use of high doses of diuretic in Ebola associated acute kidney
injury—at Emergency’s Ebola treatment centre reaffirms the
pressing need for greater accountability and clinical governance
of NGOs acting independently in medical disaster situations.
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